SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 331.73 |
| Enterprise Value ($M) | 208.48 |
| Book Value ($M) | 151.44 |
| Book Value / Share | 2.32 |
| Price / Book | 2.19 |
| NCAV ($M) | 93.33 |
| NCAV / Share | 1.43 |
| Price / NCAV | 3.55 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.46 |
| Return on Assets (ROA) | -0.34 |
| Return on Equity (ROE) | -0.43 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.97 |
| Current Ratio | 4.16 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 148.05 |
| Assets | 206.16 |
| Liabilities | 54.71 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 62.37 |
| Operating Income | -74.83 |
| Net Income | -78.98 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -48.58 |
| Cash from Investing | 8.32 |
| Cash from Financing | -2.82 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Balderton Capital VI, S.L.P. | 5.10 | 0.00 | |
| 13G/A | Generation Investment Management Llp | 10.42 | 0.00 | |
| 13D/A | Schindel Yair Chaim | 7.68 | 53.64 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 3,235 | 44,082 | 7.34 | |
| 4,813 | 8,608 | 55.91 | |
| 671 | 3,906 | 17.18 | |
| 5,174 | 17,562 | 29.46 | |
| 3,406 | 20,206 | 16.86 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SLDB – Solid Biosciences Inc. | SLRN – Acelyrin, Inc. |
| SNDX – Syndax Pharmaceuticals, Inc. | SPRB – Spruce Biosciences, Inc. |
| SPRO – Spero Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io